基质金属蛋白酶抑制剂伊洛马司他联合化疗药物对人喉癌Hep-2细胞的影响
发布时间：2018-11-27 14:11
【摘要】：目的分析基质金属蛋白酶抑制剂伊洛马司他联合化疗药物卡培他滨对人喉癌Hep-2细胞增殖及凋亡的影响，初步探讨伊洛马司他在抗喉癌侵袭过程中的作用机制，为喉癌的联合化疗提供理论依据。 方法伊洛马司他、卡培他滨两药单独和联合处理Hep-2细胞，未处理组为对照组，，采用MTT法分析Hep-2细胞的增殖活性，并采用金氏Q值判断联合用药的性质；流式细胞术检测Hep-2细胞的凋亡率； RT-PCR检测Hep-2细胞中MMP-9mRNA的表达水平。 结果①MTT示不同浓度伊洛马司他与卡培他滨对Hep-2细胞的生长均有抑制作用，且抑制率呈浓度依赖性（P0.05）；联合用药后细胞抑制率明显增高(P0.05)，且两药联合浓度为（8+100）μg/ml作用时为协同作用，（40+400）μg/ml作用时为相加作用；②流式细胞术示伊洛马司他单药组及卡培他滨单药组的凋亡率高于对照组（P0.05），联合用药组的凋亡率高于其它各组（P0.05）；③RT-PCR示伊洛马司他单药组与联合用药组的MMP-9mRNA的表达水平均低于对照组（P0.05），且联合用药组MMP-9mRNA的表达水平低于伊洛马司他单药组（P0.05），但卡培他滨单药组与对照组间MMP-9mRNA的表达水平无统计学差异（P0.05）。 结论伊洛马司他与卡培他滨联合用药可明显增强单药对喉癌Hep-2细胞的抑制效应和诱导细胞凋亡作用，伊洛马司他的作用机制可能是下调MMP-9的表达水平。
[Abstract]:Objective to investigate the effects of matrix metalloproteinase inhibitor iromatast combined with capecitabine on the proliferation and apoptosis of human laryngeal carcinoma Hep-2 cells, and to explore the mechanism of iromatrine in the process of anti-invasion of laryngeal carcinoma. To provide theoretical basis for combined chemotherapy of laryngeal carcinoma. Methods Hep-2 cells were treated with iromatrine and capecitabine alone or in combination, while the untreated group was used as control group. The proliferative activity of Hep-2 cells was analyzed by MTT assay, and the nature of combined treatment was determined by Kim's Q value. The apoptosis rate of Hep-2 cells was detected by flow cytometry and the expression of MMP-9mRNA in Hep-2 cells was detected by RT-PCR. Results 1MTT showed that the growth of Hep-2 cells was inhibited in a dose-dependent manner by different concentrations of iromatrine and capecitabine (P0.05). The cell inhibition rate was significantly increased after combined treatment (P0.05), and the synergistic effect was observed when the concentration of the two drugs was (8 100) 渭 g/ml, and the additive effect was (40 400) 渭 g/ml. 2 flow cytometry showed that the apoptotic rate of the single drug group and capecitabine group was higher than that of the control group (P0.05), and the apoptosis rate of the combination group was higher than that of the other groups (P0.05). The expression level of MMP-9mRNA in 3RT-PCR group and combination group was lower than that in control group (P0.05), and the level of MMP-9mRNA expression in combination group was lower than that in single drug group (P0.05). However, there was no significant difference in the expression of MMP-9mRNA between capecitabine group and control group (P0.05). Conclusion Iromatrine combined with capecitabine can significantly enhance the inhibitory effect and induce apoptosis of Hep-2 cells in laryngeal cancer. The mechanism of iromatrine may be to down-regulate the expression of MMP-9.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R739.65
本文编号：2361066
[Abstract]:Objective to investigate the effects of matrix metalloproteinase inhibitor iromatast combined with capecitabine on the proliferation and apoptosis of human laryngeal carcinoma Hep-2 cells, and to explore the mechanism of iromatrine in the process of anti-invasion of laryngeal carcinoma. To provide theoretical basis for combined chemotherapy of laryngeal carcinoma. Methods Hep-2 cells were treated with iromatrine and capecitabine alone or in combination, while the untreated group was used as control group. The proliferative activity of Hep-2 cells was analyzed by MTT assay, and the nature of combined treatment was determined by Kim's Q value. The apoptosis rate of Hep-2 cells was detected by flow cytometry and the expression of MMP-9mRNA in Hep-2 cells was detected by RT-PCR. Results 1MTT showed that the growth of Hep-2 cells was inhibited in a dose-dependent manner by different concentrations of iromatrine and capecitabine (P0.05). The cell inhibition rate was significantly increased after combined treatment (P0.05), and the synergistic effect was observed when the concentration of the two drugs was (8 100) 渭 g/ml, and the additive effect was (40 400) 渭 g/ml. 2 flow cytometry showed that the apoptotic rate of the single drug group and capecitabine group was higher than that of the control group (P0.05), and the apoptosis rate of the combination group was higher than that of the other groups (P0.05). The expression level of MMP-9mRNA in 3RT-PCR group and combination group was lower than that in control group (P0.05), and the level of MMP-9mRNA expression in combination group was lower than that in single drug group (P0.05). However, there was no significant difference in the expression of MMP-9mRNA between capecitabine group and control group (P0.05). Conclusion Iromatrine combined with capecitabine can significantly enhance the inhibitory effect and induce apoptosis of Hep-2 cells in laryngeal cancer. The mechanism of iromatrine may be to down-regulate the expression of MMP-9.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R739.65
【参考文献】
相关期刊论文 前10条
1 张秋颖;徐海艳;;联合顺铂对卵巢癌细胞内凋亡基因bax和bcl-2的影响[J];吉林医学;2012年08期
2 兰菁;吴宜林;;GM6001对宫颈鳞癌HCE1多细胞球体浸润人脐静脉内皮细胞的影响[J];中南大学学报(医学版);2010年08期
3 王梦琦;陈志敏;;宫颈癌组织中MMP9表达及其对细胞增殖活性影响的临床研究[J];中国现代药物应用;2010年12期
4 黄万钟;姚月华;钟瑜;鲍洁;潘达超;;长春瑞滨联合卡培他滨治疗难治性鼻咽癌的临床观察[J];中国实用医药;2009年34期
5 赵建业;朱鸣阳;杨术旺;赵红艳;许威;;卡培他滨促进胃癌细胞凋亡的实验研究[J];武警医学院学报;2008年12期
6 曹晓林;吴正虎;徐如君;林琳;张洋;朱瑾;李勇;;VEGF和TIMP-2蛋白在喉癌中的表达及其临床意义[J];中国眼耳鼻喉科杂志;2008年03期
7 艾有琴;张剑;;血浆MMP-9在喉癌术后随访中的意义[J];实用临床医学;2008年04期
8 刘钰莹;薛希均;王芳;;胸苷磷酸化酶、中期因子及CD105在喉癌组织中的表达及临床意义[J];临床耳鼻咽喉头颈外科杂志;2008年03期
9 李为;刘卫卫;白文忠;施惠晶;;MMP-7和TIMP-1在喉癌中的表达[J];中国耳鼻咽喉头颈外科;2007年07期
10 王志新;徐飞;谢启超;;肺癌组织MMP-7表达及其反义寡核苷酸对肺腺癌A_(549)细胞增殖的作用[J];四川医学;2006年11期
本文编号：2361066
本文链接：https://www.wllwen.com/yixuelunwen/yank/2361066.html
最近更新
教材专著
